Skip to Content

Karo Pharma AB KARBF

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Karo Pharma AB is a healthcare corporation. It is primarily engaged in the business activity of developing and marketing products to pharmacies and directly to the healthcare sector. The trademarks of the firm are BabySlide, Ibux, Paracet, Plantur 39, Vagisan, Triolif, Dosett, Allevo, Mabs compression, and Swereco. The projects of the companies are RORgamma; Multiple sclerosis and cancer; and T268A common cold spray. It operates in the segment of research and development for drug discovery. The company carries its business operations in Sweden and internationally, of which the majority of the revenue is generated from Sweden and Norway.

Klara Norra Kyrkogata 33
Stockholm, 111 22, Sweden
T +46 103302310
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 192